These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 14607106

  • 1. The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells.
    Zagon IS, Verderame MF, McLaughlin PJ.
    Neuropeptides; 2003 Oct; 37(5):290-7. PubMed ID: 14607106
    [Abstract] [Full Text] [Related]

  • 2. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [Abstract] [Full Text] [Related]

  • 3. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
    Kren NP, Zagon IS, McLaughlin PJ.
    Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
    [Abstract] [Full Text] [Related]

  • 4. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.
    Immunobiology; 2011 Jul; 216(1-2):173-83. PubMed ID: 20598772
    [Abstract] [Full Text] [Related]

  • 5. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ, Zagon IS, Park SS, Conway A, Donahue RN, Goldenberg D.
    BMC Cancer; 2009 Oct 18; 9():369. PubMed ID: 19835629
    [Abstract] [Full Text] [Related]

  • 6. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
    Zagon IS, Donahue RN, McLaughlin PJ.
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct 18; 297(4):R1154-61. PubMed ID: 19675283
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS, Ruth TB, McLaughlin PJ.
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan 18; 282(1):24-37. PubMed ID: 15584033
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM, Zagon IS, McLaughlin PJ.
    Brain Res Bull; 2013 Jan 18; 90():43-51. PubMed ID: 22985690
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS, Donahue R, McLaughlin PJ.
    Exp Biol Med (Maywood); 2013 May 18; 238(5):579-87. PubMed ID: 23856908
    [Abstract] [Full Text] [Related]

  • 14. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ, Zagon IS.
    Biochem Pharmacol; 2012 Sep 15; 84(6):746-55. PubMed ID: 22687282
    [Abstract] [Full Text] [Related]

  • 15. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD, Zagon IS, McLaughlin PJ.
    Exp Biol Med (Maywood); 2018 Feb 15; 243(4):361-369. PubMed ID: 29307283
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS, Sassani JW, Purushothaman I, McLaughlin PJ.
    Exp Biol Med (Maywood); 2021 Mar 15; 246(5):629-636. PubMed ID: 33203224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.